ATE513807T1 - Neuer transkriptionsfaktor, dessen herstellungsverfahren und verwendung - Google Patents
Neuer transkriptionsfaktor, dessen herstellungsverfahren und verwendungInfo
- Publication number
- ATE513807T1 ATE513807T1 AT04714032T AT04714032T ATE513807T1 AT E513807 T1 ATE513807 T1 AT E513807T1 AT 04714032 T AT04714032 T AT 04714032T AT 04714032 T AT04714032 T AT 04714032T AT E513807 T1 ATE513807 T1 AT E513807T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor
- compound
- imino compound
- production process
- transcription factor
- Prior art date
Links
- 102000040945 Transcription factor Human genes 0.000 title 1
- 108091023040 Transcription factor Proteins 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- -1 imino compound Chemical class 0.000 abstract 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- SHZXWVNJUPKTJN-UHFFFAOYSA-N Ascochlorin Natural products CC1CCC(=O)C(C)C1C=CC(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O SHZXWVNJUPKTJN-UHFFFAOYSA-N 0.000 abstract 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 abstract 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000016978 Orphan receptors Human genes 0.000 abstract 1
- 108070000031 Orphan receptors Proteins 0.000 abstract 1
- 102000007451 Steroid Receptors Human genes 0.000 abstract 1
- 108010085012 Steroid Receptors Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- SETVRSKZJJWOPA-FLDGXQSCSA-N ascochlorin Chemical compound C[C@@H]1CCC(=O)[C@H](C)[C@@]1(C)\C=C\C(\C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O SETVRSKZJJWOPA-FLDGXQSCSA-N 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 102000006255 nuclear receptors Human genes 0.000 abstract 1
- 108020004017 nuclear receptors Proteins 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/18—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003092682 | 2003-02-24 | ||
| PCT/JP2004/002110 WO2004074236A1 (ja) | 2003-02-24 | 2004-02-24 | 新規転写因子、その製法および用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE513807T1 true ATE513807T1 (de) | 2011-07-15 |
Family
ID=32905960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04714032T ATE513807T1 (de) | 2003-02-24 | 2004-02-24 | Neuer transkriptionsfaktor, dessen herstellungsverfahren und verwendung |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7629471B2 (de) |
| EP (1) | EP1616856B1 (de) |
| JP (1) | JP4789618B2 (de) |
| AT (1) | ATE513807T1 (de) |
| CA (1) | CA2516698C (de) |
| WO (1) | WO2004074236A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432306B2 (en) | 2005-09-07 | 2008-10-07 | Nrl Pharma, Inc. | Method for preparing novel transcription factors and use |
| JP2009051731A (ja) * | 2005-11-25 | 2009-03-12 | Yokohama Tlo Co Ltd | 新規アスコクロリン誘導体化合物及びそれを含有する医薬組成物 |
| WO2013042782A1 (ja) * | 2011-09-22 | 2013-03-28 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| CN108473408B (zh) | 2016-01-05 | 2021-08-17 | 星野达雄 | 壳二孢氯素衍生物及其作为ampk激活剂的用途 |
| EP3624849A4 (de) | 2017-05-18 | 2021-02-24 | Tatsuo Hoshino | Kombinationstherapie mit ascochlorinderivat |
| WO2018216821A1 (en) * | 2017-05-23 | 2018-11-29 | Nrl Pharma, Inc. | Use of ascochlorin derivative for combination therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0737402B2 (ja) * | 1987-06-09 | 1995-04-26 | 武田薬品工業株式会社 | フェノール誘導体、その製造法およびそれを含んでなる医薬組成物 |
| KR20010093825A (ko) * | 1998-12-14 | 2001-10-29 | 추후기재 | 신규의 핵수용체 리간드 |
| TR200202077T2 (tr) * | 1999-03-11 | 2002-11-21 | Nuclear Receptor Research Limited | Prar nükleer reseptörleri için yeni ligandlar |
| US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
-
2004
- 2004-02-24 JP JP2005502807A patent/JP4789618B2/ja not_active Expired - Fee Related
- 2004-02-24 US US10/546,854 patent/US7629471B2/en not_active Expired - Fee Related
- 2004-02-24 WO PCT/JP2004/002110 patent/WO2004074236A1/ja not_active Ceased
- 2004-02-24 CA CA2516698A patent/CA2516698C/en not_active Expired - Fee Related
- 2004-02-24 AT AT04714032T patent/ATE513807T1/de not_active IP Right Cessation
- 2004-02-24 EP EP04714032A patent/EP1616856B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1616856A1 (de) | 2006-01-18 |
| EP1616856B1 (de) | 2011-06-22 |
| US7629471B2 (en) | 2009-12-08 |
| JP4789618B2 (ja) | 2011-10-12 |
| JPWO2004074236A1 (ja) | 2006-06-01 |
| CA2516698C (en) | 2012-01-31 |
| CA2516698A1 (en) | 2004-09-02 |
| US20060247307A1 (en) | 2006-11-02 |
| EP1616856A4 (de) | 2007-03-28 |
| WO2004074236A1 (ja) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2515596A1 (en) | Cannabinoid receptor ligands and uses thereof | |
| MXPA05010164A (es) | Ligandos de receptores de canabinoides y sus usos. | |
| TW200510419A (en) | Cannabinoid receptor ligands and uses thereof | |
| MXPA05013294A (es) | Ligandos del receptor de cannabinoides y usos de los mismos. | |
| CA2503900A1 (en) | Purine compounds and use thereof as cannabinoid receptor ligands | |
| CY2017046I2 (el) | Αντισωματα ειδικα για το cd22 και η θεραπευτικη και διαγνωστικη χρηση τους | |
| MXPA05011922A (es) | Ligandos del receptor de cannabinoides y sus usos. | |
| MX2007005205A (es) | Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma. | |
| MX2010003718A (es) | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. | |
| PH12015500507A1 (en) | Humanized antibodies to amyloid beta | |
| DE60333121D1 (de) | Pers 14.18, der gd2 bindet und seine fusion mit il-2 | |
| NO20061974L (no) | Salter og polymorfer av en potent antidiabetisk forbindelse | |
| HUP0000944A2 (hu) | A 2-amino-4-(4-fluor-benzilamino)-1-etoxikarbonil-aminobenzol új módosulatai és eljárás előállításukra | |
| WO2005056522A3 (en) | Indole compounds | |
| ATE513807T1 (de) | Neuer transkriptionsfaktor, dessen herstellungsverfahren und verwendung | |
| SE9804003D0 (sv) | A method of producing drug particles | |
| DE60322412D1 (de) | Pharmazeutische feste Dispersionen von Modafinil-Verbindungen | |
| WO2008127361A3 (en) | Synthesis of enone intermediate | |
| ECSP055626A (es) | Nuevos conjugados de efectores, procedimientos para su preparación y su uso farmacéutico | |
| BRPI0519443A2 (pt) | composto orgÂnicos | |
| ATE304709T1 (de) | Substanzen mit verzweigten linkermolekülen | |
| ATE435020T1 (de) | Oligo-beta-(1,3)-glucan und monoklonale antikörper gegen krebs | |
| AU2003272072A8 (en) | A process to prepare pioglitazone via several intermediates. | |
| TW200633963A (en) | Novel cyclohexane derivatives | |
| ATE403649T1 (de) | Neue imidazolderivative, deren herstellung und deren verwendung als medikament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |